Sano et al.13–15 found that NLRP3 inflammasome-targeted therapies might be effective methods to reduce infarct size and prevent heart failure following AMI and transverse aortic constriction (TAC). The gene discussed is NLRP3; the disease is persistent truncus arteriosus.